Method for inhibiting growth of cancer cells and cell telomere and diseases of cell proliferation by using heteroannelated anthraquinone derivative compounds

ABSTRACT

A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (I): 
     
       
         
         
             
             
         
       
     
     wherein R 1  is a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a group consisting of (CH 2 ) n X, a straight (CH 2 ) n  alkyl group, a (CH 2 ) n  alkoxyl group, a branched (CH 2 ) n  alkyl group, a C 3 ˜C 12  nephthenic group, and a C 3 ˜C 12  cyclic alkoxyl group, wherein 1≦n≦12, and X is a halogen, iii) a third substituent being one selected from a group consisting of a straight C 1 ˜C 8  alkyl group with a double-bond, a C 1 ˜C 8  alkoxyl group with a double-bond, a branched C 1 ˜C 8  alkyl group with a double-bond and a C 3 ˜C 8  nephthenic group with a double-bond, and iv) a fourth substituent of a C 5 ˜C 12  heterocyclic group.

CROSS-REFERENCES TO RELATED APPLICATIONS

This is a divisional application of U.S. patent application Ser. No. 12/193,564 filed on Aug. 18, 2008 which is incorporated herein by reference as if fully set forth.

FIELD OF THE INVENTION

The present invention relates to heteroannelated anthraquinone derivatives for inhibiting a proliferation activity of a cancer cell, and more particularly to a series of heteroannelated anthraquinone derivatives and the synthesis method thereof.

BACKGROUND OF THE INVENTION

In normal somatic cells, the telomere, which is located at the end of a chromosome, gets shortened at each time of cell mitosis. When the telomere is shortened to some level, the cell will lose the ability of replication and go into apoptosis stage. Telomerase, which is a ribonucleoprotein, acts on the telomere in a eukaryocyte, so as to prolong or maintain the length of the telomere. A telomerase mainly includes two portions; one is a protein sub-unit with activity of reverse transcription, i.e. the human telomerase reverse transcriptase (hTERT), and the other one is an RNA template for synthesizing repeated sequences of the telomerase, i.e. the human telomerase RNA component (hTR), wherein the RNA template includes the single RNA sequence, -AAUCCC, which is complementary to the telomerase sequence. Telomerase activity is rarely detected in normal human somatic cells, but is usually detected in the cells that keep proliferating, such as hematopoietic cells, embryogenic cells, stem cells, etc. It is estimated that about 85-90% of human tumor cells have telomerase activity, and that is the reason why tumor cells do not go into apoptosis like a normal cell and can keep proliferating (Urquidi et al., Annu. Rev. Med. 2000, 51, 65-79). Reductions in hTERT mRNA expression level and telomerase activity are observed during the processes of cell going aged or immortalized (Bestilny et al., Cancer Res. 1996, 56, 3796-802). Furthermore, the telomerase activity of a somatic cell that should not express the telomerase activity could be reproduced by introduction of the hTERT cDNA thereinto for a high level expression of telomerase activity (Bodnar et al., Science. 1998, 279, 349-52).

The telomere at chromosome ends of eukaryotic cells is guanine-rich. In normal physiological conditions, the single strand DNA of the telomere spontaneously forms a G-quadruplex structure. The G-quadruplex structure includes two portions, wherein one is a small loop composed of TTA, and the other one is a guanine-tetrad composed of four guanines formed by cyclic hydrogen bonds. In order to inhibit the differentiation of tumor cells, an alternative besides the direct inhibition to telomerase activity is to stabilize the G-quadruplex structure for inhibiting its reaction with the complementary single strand RNA (AAUCCC), so as to prevent the telomerase from extending the telomere. Chromosome replications of tumor cells may be inhibited by the mentioned method, so as to achieve the anti-cancer effect directly or indirectly (Smogorzewska et al., Annu. Rev. Biochem. 2004, 73, 177-208).

It is observed in current studies that anthraquinone can stabilize the G-quadruplex structure for its formula with plane tri-cyclic structure. According to the researches to the quindoline derivatives (10H-indolo[3,2-b]quinoline) with tetra-cyclic structure, berberin with non-plane polycyclic structure and the analogs synthesized therefrom, it is known that the aromatic groups of the mentioned compounds play an important role in the bonding to the G-quadruplex structure. Over-expressions of known oncogenes usually induce cancers and are associated with many cell proliferation disorders, such as chronic lymphocytic leukemia, esophagus cancer, myeloma, etc. In additions, those genes also participate in many pathological and physiological processes. Many experiments have proved that over-expressions of tumor suppressor genes play important role in the prevention and treatment of tumors. Therefore, the research and development of the drugs for curing cell proliferation disorders can be applied in the cure of human cancers, just like the disclosures of Canadian Patent No. 2,428,206.

Although it has been published that a heteroannelated anthraquinone derivative can be synthesized by an acylation reaction of 1,2-diaminoanthraquinone to obtain a bis-substituent derivative, followed by a condensation reaction. However, this method only discloses the substituent of aromatic groups, and has a poor production rate (Peng et al., J. Org. Chem. 2005, 70, 10524-31).

Based on the above, the present invention provides heteroannelated anthraquinone derivatives and the synthesis method thereof, which is accomplished by preserving the chromophore group with plane tri-cyclic structure and the carbonyl groups at 9 and 10, which have better binding ability, then changing the tri-cyclic structure into tetra-cyclic structure and adding various side chains derived from different modified substituents, so as to synthesize a series of heteroannelated anthraquinone derivatives.

SUMMARY OF THE INVENTION

The present invention provides a series of heteroannelated anthraquinone derivatives for inhibiting the proliferation activity of cancer cells, which facilitate the study and application regarding cancer cells.

In accordance with the first aspect of the present invention, a heteroannelated anthraquinone derivative compound is provided. The compound is represented by a formula (I):

wherein R₁ is a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a group consisting of (CH₂)_(n)X, a straight (CH₂)_(n) alkyl group, a (CH₂)_(n) alkoxyl group, a branched (CH₂)_(n) alkyl group, a C₃˜C₁₂ nephthenic group, and a C₃˜C₁₂ cyclic alkoxyl group, wherein 1≦n≦12, and X is a halogen, iii) a third substituent being one selected from a group consisting of a straight C₁˜C₈ alkyl group with a double-bond, a C₁˜C₈ alkoxyl group with a double-bond, a branched C₁˜C₈ alkyl group with a double-bond and a C₃˜C₈ nephthenic group with a double-bond, and iv) a fourth substituent of a C₅˜C₁₂ heterocyclic group, wherein one of the nephthenic group and the heterocyclic group further has at least one of an ortho-substitution, a meta-substitution and a para-substitution, and comprises at least a fifth substituent for any of the substitutions being one selected from a group consisting of an alkyl group with a C₁˜C₃ substituent branch, an amino group, a nitro group, a hydroxyl group and a cyan group, a C₁˜C₅ alkyl group, a halogen substituted C₁˜C₅ alkyl group, a C₁˜C₅ alkoxyl group, a halogen substituted C₁˜C₅ alkoxyl group, a C₁˜C₅ cyclic alkoxyl group, and a halogen substituted C₁-C₅ cyclic alkoxyl group.

Preferably, the halogen is one selected from a group consisting of a fluorine, a chlorine, a bromine and an iodine.

Preferably, the second substituent is one selected from a group consisting of a methyl group, an ethyl group, a propyl group, a butyl group, an isobutyl group, a pentyl group, an isopentyl group, a cyclopentyl group, a heptyl group, an isoheptyl group, a cycloheptyl group, an octyl group, an isooctyl group, a cyclooctyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₅ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₅ alkyl group, alkoxyl derivatives of the mentioned alkyl groups, and halogenated derivatives of the mentioned alkyl groups.

Preferably, the third substituent is one selected from a group consisting of a vinyl group, a propenyl group, a butenyl group, an isobutenyl group, a pentenyl group, an isopentenyl group, a cyclopentenyl group, a hexenyl group, a cyclohexenyl group, a heptenyl group, an cycloheptenyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₃ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₃ alkyl group, alkoxyl derivatives of the mentioned groups, and halogenated derivatives of the mentioned groups.

Preferably, the heteroannelated anthraquinone derivative compound is used as an effective component together with an excipient to provide a pharmaceutic composition for inhibiting one selected from a group consisting of a growth of a cancer cell, a disease of cell proliferation, and a growth of cell telomere.

In accordance with the second aspect of the present invention, a heteroannelated anthraquinone derivative compound is provided. The compound is represented by a formula (II):

Preferably, the heteroannelated anthraquinone derivative compound is used as an effective component together with an excipient to provide a pharmaceutic composition for inhibiting one selected from a group consisting of a growth of a cancer cell, a disease of cell proliferation, and a growth of cell telomere.

In accordance with the third aspect of the present invention, a heteroannelated anthraquinone derivative compound is provided. The compound is represented by a formula (III):

wherein either one of R₂ and R₃ is one of i) a first substituent being one of a hydryl group and a sulfuryl-group, and ii) a second substituent being one selected from a group consisting of a C₁˜C₈ alkyl group, a C₁˜C₈ alkoxyl group, a C₃˜C₈ nephthenic group, and a C₃˜C₈ cyclic alkoxyl group, a straight alkyl group with a branch substitutent, a nephthenic group with a branch substitutent by a straight C₁˜C₅ alkyl group and halogenated derivatives of the mentioned substituent groups.

Preferably, the second substituent is one selected from a group consisting of a methyl group, an ethyl group, a propyl group, a butyl group, an isobutyl group, a pentyl group, an isopentyl group, a cyclopentyl group, a heptyl group, an isoheptyl group, a cycloheptyl group, an octyl group, an isooctyl group, a cyclooctyl group, a phenyl group, a benzyl group, a phenethyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₃ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₃ alkyl group, alkoxyl derivatives of the mentioned substituent groups, and halogenated derivatives of the mentioned substituent groups.

Preferably, the heteroannelated anthraquinone derivative is used as an effective component together with an excipient to provide a pharmaceutic composition for inhibiting one selected from a group consisting of a growth of a cancer cell, a disease of cell proliferation, and a growth of cell telomere.

In accordance with the fourth aspect of the present invention, a heteroannelated anthraquinone derivative compound is provided. The compound is represented by a formula (IV):

wherein R₄ is one selected from a group consisting of a hydryl group, a C₁˜C_(a) alkyl group, a C₁˜C₄ alkoxyl group, a C₁-C₄ ketone group, a straight alkyl group with a branch substituted by a straight C₁˜C₃ alkyl group, a halogen substituted C₁˜C₄ alkyl group, and a C₁˜C₄ alkoxyl group.

Preferably, A compound as claimed in claim 12, being used as an effective component together with an excipient to provide a pharmaceutic composition for inhibiting one selected from a group consisting of a growth of a cancer cell, a disease of cell proliferation, and a growth of cell telomere.

In accordance with the fifth aspect of the present invention, a method for manufacturing a compound having the formula (I) is provided. The method includes steps of a) dissolving a diaminoanthraquinone in a dimethylformamide solution for forming a solution A, b) adding and dissolving a chloroacetyl chloride in the solution A for forming a solution B, c) mixing and reacting the solution B by a reverse flow method, and then transferring the solution B into an icy water for forming a solution C, d) filtering the solution C for obtaining a precipitate, and e) washing the precipitate by using an ethanol for obtaining the compound of the formula (I).

In accordance with the sixth aspect of the present invention, a method for manufacturing a compound having the formula (I) is provided. The method includes steps of a) dissolving a diaminoanthraquinone in a dimethylformamide solution for forming a solution A, b) adding and dissolving a reagent in the solution A for forming a solution B, wherein the reagent is one of a benzaldehyde and a carbon disulfide, c) catalyzing a reaction of the solution B by adding a concentrated sulfuric acid thereinto, and then transferring the solution B into an ice water for forming a solution C, d) filtering the solution C for obtaining a precipitate, and e) washing the precipitate by using an ethanol for obtaining the compound of the formula (I), wherein when the reagent is the carbon disulfide, a triethylamine is further added into the solution B before the step c).

In accordance with the seventh aspect of the present invention, a method for manufacturing a compound having the formula (III) is provided. The method includes steps of a) dissolving a diaminoanthraquinone in an acetone for forming a solution A, b) adding a concentrated sulfuric acid into the solution A for forming a solution B, c) transferring the solution B into a potassium carbonate column for obtaining a solution C, and d) using a methanol to crystallize the compound of the formula (III) in the solution C.

Preferably, the step b) is performed in a room temperature.

In accordance with the eighth aspect of the present invention, a method for manufacturing a compound having the formula (IV) is provided. The method includes steps of a) dissolving a diaminoanthraquinone in a dimethylformamide solution for forming a solution A, b) adding a glyoxal ethanol solution into the solution A for forming a solution B, c) reacting the solution B by a reverse flow reaction, d) filtering the solution B for obtaining a precipitate, and e) washing the precipitate by using a hot alcohol and a dichloromethane for separating out the compound of the formula (IV).

Alternatively, in some steps of the above-mentioned methods, the production rate will increase if the solvents used for dissolving the diaminoanthraquinone contain less water. In the purification steps for the products, alcohol could be used for crystallization; alternatively, hot alcohol could be used for washing the products. The products with high solubility could be dissolved in alcohol before crystallization. The products with low solubility need to be washed by hot alcohol to wash out initial material or impurities and by-products generated in the reaction. Compared with recrystallization, although parts of products would be lost in the washing steps, it would be easier to obtain the purified products.

The compound provided in the present invention could be supplied with excipients, carriers or diluent, such starch or binder like carboxymethyl cellulose (CMC), so as to prepare granulated pill, tablet, or capsule. Alternatively, the compound could be dissolved in phosphate buffer for adjusting the pH thereof, so as to prepare injection. The compound could be supplied with penetration enhancer, so as to prepare absorbate by skin.

Additional objects and advantages of the invention will be set forth in the following descriptions.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention will now be described more specifically with the experiment results of the following embodiments. It is to be noted that the following descriptions of preferred embodiments of this invention are presented herein for the purposes of illustration and description only; it is not intended to be exhaustive or to be limited to the precise form disclosed.

Concretely speaking, the method for manufacturing the heteroannelated anthraquinone derivative includes cyclization and condensation reactions.

Embodiment 1 2-Methyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione, No. 2

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in 30 mL of N,N-dimethylformamide, and chloroacetyl chloride (0.5 mL, 6 mmol) is added thereinto. After ten hours of mixing and reacting by a reverse flow, the mixture is transferred into 200 mL of icy water. After filtering, the precipitate is collected and washed by hot alcohol, so as to obtain the black compound No. 2.

The compound No. 2 has the following characterstics: MW 262.0724 (C₁₆H₉N₂O₂); R_(f): 0.79 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 1667 (CO); EI-MS m/z: 262 (M⁺, 100%); ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): 2.72 (3H, s, —CH₃), 7.75-7.82 (2H, m, Ar—H_(7,10)), 7.93 (1H, d, J=8.4 Hz, Ar—H₅), 8.13 (1H, d, J=8.4 Hz, Ar—H₄), 8.19-8.23 (1H, m, Ar—H_(8,9)), 11.01 (1H, br, —NH); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm): 23.89, 120.23, 121.22, 125.29, 126.19, 126.75, 127.19, 128.17, 128.87, 132.98, 134.18, 134.42, 148.22, 158.09, 182.43 (CO), 185.13 (CO).

Embodiment 2 2-Chloroacetyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione, No. 3

Except controlling the reacting temperature in 50-60° C., all steps are identical with the steps for manufacturing the compound No. 2, and the yellowish brown compound No. 3 can be obtained.

The compound No. 3 has the following characterstics: MW 296.0353 (C₁₆H₉N₂O₂Cl); R_(f): 0.5 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3359(NH), 1660 (CO); HRMS (ESI-TOF) m/z: calcd for C₁₆H₁₀N₂O₂Cl⁺ [M+H]⁺: 297.0425, found: 297.0426; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): 4.92 (2H, s, —CH₂Cl), 7.80-7.83 (2H, m, Ar—H_(7,10)), 8.08 (1H, d, J=8.4 Hz, Ar—H₅), 8.24 (111, d, J=8.4 Hz, Ar—H₄), δ8.26-8.35 (2H, m, Ar—H_(8,9)), δ11.21 (1H, br, —NH); and ¹³C-NMR (75 MHz, DMSO) δ (ppm): 37.80, 119.35, 121.27, 125.95, 126.83, 127.40, 129.06, 132.35, 133.47, 133.64, 134.88, 135.10, 148.89, 156.93, 183.04 (CO), 183.83 (CO).

Embodiment 3 2-Ethyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione, No. 4

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) was dissolved in dimethylformamide (30 mL), and propionaldehyde (0.29 g, 5 mmol) is added thereinto. Concentrated sulfuric acid (0.1 mL) is added thereinto for catalyzation. After mixing and reacting at room temperature for one hour, the reacted mixture is transferred into 200 mL of icy water and is extracted by using dichloromethane. The extract is dried, and crystallized by using alcohol, so as to obtain the brown compound No. 4.

The compound No. 4 has the following characterstics: MW 276.0899 (C₁₇H₁₂N₂O₂); R_(f): 0.75 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 1669 (CO); HRMS (ESI-TOF) m/z: calcd for C₁₇K₃N₂O₂ ⁺[M+H]⁺: 277.0971, found: 277.0975 calcd for C₁₇H₁₂N₂O₂Na⁺ [M+Na]⁺: 299.0971, found: 299.0794; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): 1.51 (3H, t, J=7.5 Hz, —CH₃), 3.05 (2H, q, J=7.5 Hz, —CH₂—), 7.73-7.81 (2H, m, Ar—H_(7,10)), 7.99 (1H, d, J=8.4 Hz, Ar—H₅), δ8.16 (1H, d, J=8.4 Hz, Ar—H₄), δ8.21-8.23 (1H, m, Ar—H₉), δ8.27-8.31 (1H, m, Ar—H₈), δ10.85 (1H, br, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 11.87, 22.89, 117.74, 121.50, 125.21, 126.47, 127.55, 128.21, 132.72, 133.24, 133.72, 133.99, 134.37, 148.90, 161.64, 182.81 (CO), 185.15 (CO).

Embodiment 4 2-Isopropyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione, No. 5

All steps for manufacturing the yellow compound No. 5 are identical with the steps of Embodiment 3, except that propionaldehyde is substituted by isobutyraldehyde (0.41 g, 5 mmol).

The compound No. 5 has the following characterstics: MW 290.1055 (C₁₈H₁₄N₂O₂); R_(f): 0.7 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3445 (NH), 1662 (CO); HRMS (ESI-TOF) m/z: calcd for C₁₈H₁₅N₂O₂ ⁺ [M+H]⁺: 291.1120, found: 291.1123; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ1.56 (6H, d, J=6.6 Hz, —CH₃), δ3.40 (1H, sp, J=6.6 Hz, —CH—), δ7.78-7.85 (2H, m, Ar—H_(7,10)), δ8.11 (1H, d, J=8.4 Hz, Ar—H₅), δ8.23 (1H, d, J=8.4 Hz, Ar—H₄), δ8.25-8.36 (2H, m, Ar—H_(8,9)), δ10.88 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 21.15, 29.21, 117.66, 121.36, 125.21, 126.32, 127.42, 128.05, 132.49, 133.10, 133.61, 133.86, 134.24, 148.71, 165.35, 181.05 (CO), 182.73 (CO).

Embodiment 5 2-Butyl-1(3)H— anthra[1,2-d]imidazole-6,11-dione, No. 6

All steps for manufacturing the brown compound No. 6 are identical with the steps of Embodiment 3, except that propionaldehyde is substituted by pentanal (0.45 g, 5 mmol).

The compound 6 has the following characterstics: MW 304.1212 (C₁₉H₁₆N₂O₂); R_(f): 0.65 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 1669 (CO); HRMS (ESI-TOF) m/z: calcd for C₁₉H₁₇N₂O₂ ⁺ [M+H]⁺: 305.1276, found: 305.1282 calcd for C₁₉H₁₅N₂O₂ ⁻ [M−H]⁻: 303.1131, found: 303.1135; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ1.00 (3H, t, J=7.2 Hz, —CH₃), δ1.50 (2H, sx, J=7.5 Hz, —CH₂—), δ1.93 (2H, qt, J=7.8 Hz δ3.04 (2H, t, J=7.5 Hz, —CH₂—), δ7.62-7.83 (2H, m, Ar—H_(7,10)), δ8.03 (1H, d, J=8.4 Hz, Ar—H₅), δ8.20, 1H, d, J=8.1 Hz, Ar—H₄), δ8.24-8.35 (2H, m, Ar—H_(8,9)), δ10.83 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 12.98, 21.78, 28.60, 29.27, 117.32, 121.07, 124.64, 125.98, 127.08, 127.83, 132.17, 132.84, 133.20, 133.61, 133.86, 148.25, 160.29, 182.31 (CO), 184.78 (CO).

Embodiment 6 2-sec-Butyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione, No. 7

All steps for manufacturing the yellow compound No. 7 are identical with the steps of Embodiment 3, except that propionaldehyde is substituted by methylbutyraldehyde (0.46 g, 5 mmol).

The compound No. 7 has the following characterstics: MW 304.1212 (C₁₉H₁₆N₂O₂); R_(f): 0.57 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 1665 (CO); HRMS (ESI-TOF) m/z: calcd for C₁₉H₁₅H₁₇N₂O₂ ⁺ [M+H]⁺: 305.1276, found: 305.1280 calcd for C₁₉H₁₅N₂O₂ ⁻ [M−H]⁻: 303.1131, found: 303.1137; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ1.00 (3H, t, J=7.2 Hz, —CH₃), δ1.52 (3H, d, J=6.9 Hz, —CH₃), δ1.82-2.02 (2H, m, —CH₂—), δ3.04 (1H, sx, J=7.2 Hz, —CH—), δ7.62-7.83 (2H, m, Ar—H_(7,10)), δ8.03 (1H, d, J=8.4 Hz, Ar—H₅), δ8.20 (1H, d, J=8.1 Hz, Ar—H₄), δ8.24-8.35 (2H, m, Ar—H₈₉), δ10.83 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 11.09, 18.09, 28.40, 35.71, 117.39, 121.07, 124.75, 125.95, 127.09, 127.84, 131.92, 132.83, 133.22, 133.59, 133.87, 148.06, 164.30, 182.31 (CO), 184.82 (CO).

Embodiment 7 2-tert-Butyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione No. 8

All steps for manufacturing the yellow compound No. 8 are identical with the steps of Embodiment 3, except that propionaldehyde is substituted by trimethylacetaldehyde (0.46 g, 5 mmol).

The compound No. 8 has the following characterstics: MW 304.1212 (C₁₉H₁₆N₂O₂); R_(f): 0.8 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3568(NH), 1664 (CO); HRMS (ESI-TOF) m/z: calcd for C₁₉H₁₇N₂O₂ ⁺ [M+H]⁺: 305.1276, found: 305.1283 calcd for C₁₉H₁₅N₂O₂ ⁻ [M−H]⁻: 303.1131, found: 303.1136; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ1.58 (9H, s, —C(CH₃)₃), δ7.77-7.84 (2H, m, Ar—H_(7,10)), δ8.08 (1H, d, J=8.4 Hz, Ar—H₅), δ8.21 (1H, d, J=8.4 Hz, Ar—H₄), δ8.25-8.28 (1H, m, Ar—H₈), δ8.33-8.36 (1H, m, Ar—H₉), δ10.83 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 29.24, 117.79, 121.47, 125.41, 126.39, 127.56, 128.17, 132.70, 133.23, 133.74, 133.96, 134.37, 148.73, 168.00, 182.77 (CO), 185.26 (CO).

Embodiment 8 2-Heptyl-1(3)H-anthra [1,2-d]imidazole-6,11-dione, No. 9

All steps for manufacturing the brown compound No. 9 are identical with the steps of Embodiment 3, except that propionaldehyde is substituted by octanal (0.29 g, 5 mmol).

The compound No. 9 has the following characterstics: MW 346.1681 (C₂₂H₂₂N₂ ^(O) ₂); R_(f): 0.85 (ethyl acetate:dichloromethane=1:4); IR IR (KBr) cm⁻: 3447(NH), 1664 (CO); HRMS (ESI-TOF) m/z: calcd for C₂₂H₂₃N₂O₂ ⁺ [M+H]⁺: 347.1754, found: 347.1752; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ0.87-0.91 (3H, m, —CH₃), δ1.26-1.35 (6H, m, δ1.56 (2H, sx, J=7.0 Hz, —CH₂—), δ2.36 (2H, q, J=7.0 Hz, —CH₂—), δ2.71 (2H, t, J=7.0 Hz, —CH₂—), δ7.75-7.81 (2H, m, Ar—H_(7,10)), δ8.04 (1H, d, J=8.0 Hz, Ar—H₅), δ8.17 (1H, d, J=8.0 Hz, Ar—H₄), δ8.23-8.25 (1H, m, Ar—H₈), δ8.31-8.33 (1H, m, Ar—H₉), δ10.93 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 14.08, 22.63, 27.99, 28.79, 29.24, 29.46, 31.79, 117.49, 121.66, 125.28, 126.37, 127.54, 130.56, 133.27, 133.67, 134.06, 134.31, 137.37, 149.40, 158.89, 182.69 (CO), 185.25 (CO).

Embodiment 9 (E)-2-(But-1-enyl)-1(3)H-anthra[1,2-d]imidazole-6,11-dione, No. 10

All steps for manufacturing the brown compound No. 10 are identical with the steps of Embodiment 3, except that propionaldehyde is substituted by trans-2-pentenal (0.46 g, 5 mmol).

The compound No. 10 has the following characterstics: MW 302.1055 (C₁₉H₁₅N₂O₂); R_(f): 0.57 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 1664 (CO); EI-MS m/z: 302 (M⁺, 100%); ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ0.98 (3H, t, J=6.9 Hz, —CH₃), δ1.94-1.98 (2H, m, —CH₂—), δ6.16-6.29 (1H, m, —CH—), δ6.51 (1H, d, J=18 Hz, —CH—), δ7.68 (1H, d, J=8.4 Hz, Ar—H₅), δ7.82-7.89 (2H, m, Ar—H_(7,10)), δ8.14 (1H, d, J=8.1 Hz, Ar—H₄), δ8.27-8.35 (2H, m, Ar—H_(8,9)), δ10.74 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 14.39, 27.40, 117.37, 120.03, 121.07, 124.75, 125.95, 127.09, 127.84, 131.92, 132.83, 133.22, 133.59, 133.87, 134.90, 135.37, 149.06, 182.73 (CO), 185.18 (CO).

Embodiment 10 2-Mercapto-1(3)H-anthra[1,2-c]imidazole-6,11-dione, No. 23

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in N,N-dimethylformamide (30 mL), and triethylamine (3 mL) is further added thereinto after carbon disulfide (0.4 g, 5 mmol) is added thereinto. After mixing in room temperature and performing reverse flow for ten hours, the reacted mixture is transferred into 200 mL of icy water. After filtering, the precipitate is collected and washed by hot alcohol, so as to obtain reddle compound No. 23 with melting point of 407-409° C., and the production rate is 80%.

The compound No. 23 has the following characterstics: MW 280.0306 (C₁₅H₈N₂O₂S); R_(f): 0.80 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3221(NH), 3192(NH), 1665(CO); HRMS (ESI-TOF) m/z: calcd for C₁₅H₉N₂O₂S⁺ [M+H]⁺: 281.0379, found: 281.0389; ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): δ7.54 (1H, d, J=8.1 Hz, Ar—H₅), δ8.02 (1H, d, J=8.1 Hz, Ar—H₄), δ7.91-7.94 (2H, m, Ar—H_(7,10)), δ8.18-8.22 (2H, m, Ar—H_(8,9)), δ12.73 (1H, s, —NH), δ13.29 (1H, s, —NH); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm): 113.89, 115.27, 122.41, 126.26, 126.76, 126.88, 130.95, 132.89, 133.06, 134.25, 134.47, 138.19, 172.89, 181.79 (CO), 182.46 (CO).

Embodiment 11 2-Phenyl-1(3)H-anthra[1,2-c]imidazole-6,11-dione No 11

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in dimethylformamide (30 mL), and concentrated sulfuric acid (0.1 mL) is further added thereinto for catalyzation after benzaldehyde (0.6 mL, 5 mmol) is added thereinto. After mixing and reacting in room temperature for one hour, the reacted mixture is transferred into 200 mL of icy water. After filtering, the precipitate is collected and washed by hot alcohol, so as to obtain yellowish brown compound No. 11.

The compound No. 11 has the following characterstics: MW 324.0899 (C₂₁H₁₂N₂O₂); R_(f): 0.55 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻: 3296(NH), 1660 (CO); EI-MS m/z: 324(M⁺, 100.00%), 325(19%); HRMS (ESI-TOF) m/z: calcd for C₂₁H₁₃N₂O₂ ⁺ [M+H]⁺: 325.0971, found: 325.0973; ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): δ7.57 (3H, t, J=3 Hz, Ar′—H_(3,4,5)), δ7.89 (2H, m, Ar—H_(7,10)), δ8.03 (1H, d, J=8.4 Hz, Ar—H₅), δ8.08 (1H, d, J=8.4 Hz, Ar—H₄), δ8.16 (2H, m, Ar—H_(8,9)), δ8.40 (2H, dd, J=6, 3 Hz, Ar′—H_(2,6)); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm): 119.62, 121.72, 125.06, 126.85, 127.42, 128.79, 128.86, 129.41, 129.50, 131.72, 133.72, 133.77, 134.92, 135.07, 149.26, 158.25, 183.06 (CO), 183.79 (CO).

Embodiment 12 2-(4-N,N-Dimethylamino)phenyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione, No. 12

All steps for manufacturing the deep brown compound No. 12 are identical with the steps of Embodiment 11, except that benzaldehyde is substituted by 4-dimethylaminobenzaldehyde (0.77 g, 5 mmol).

The compound No. 12 has the following characterstics: MW 367.1321 (C₂₃H₁₇N₃O₂); R_(f): 0.6 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3404(NH), 1659(CO); EI-MS m/z: 366(27%), 367 (M⁺, 100.00%), 368 (20%); HRMS (ESI-TOF) m/z: calcd for C₂₃H₁₈N₃O₂ ⁺ [M+H]⁺: 368.1393, found: 368.1393; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ3.09 (6H, s, —N(CH₃)₂), δ6.81 (2H, d, Ar—H), δ7.79-7.82 (3H, m, Ar—H), δ8.03-8.22 (3H, m, Ar—H), δ8.27-8.36 (2H, m, Ar—H), δ11.10 (1H, br, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 39.95, 111.65, 115.23, 117.13, 121.83, 124.24, 126.33, 127.37, 127.44, 128.27, 133.27, 133.45, 133.54, 134.12, 150.11, 152.10, 157.59, 182.47 (CO), 185.09 (CO).

Embodiment 13 2-(4-Nitrophenyl)-1(3)H-anthra[1,2-c]imidazole-6,11-dione, No. 13

All steps for manufacturing the deep brown compound No. 13 are identical with the steps of Embodiment 11, except that benzaldehyde is substituted by 4-nitrobenzaldehyde (0.78 g, 5 mmol).

The compound No. 13 has the following characterstics: MW 369.0750 (C₂₁H₁₁N₃O₄); R_(f): 0.6 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3460(NH), 1657 (CO), 1517, 1345(NO₂); EI-MS m/z: 249(100%), 369(M⁺, 35%); HRMS (ESI-TOF) m/z: calcd for C₂₁H₁₂N₃O₄ ⁺ ⁻ [M+H]⁺: 370.0822, found: 370.0823; ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): δ7.79-7.82 (3H, m, Ar—H_(7,10)), δ7.14 (1H, d, J=8.1 Hz, Ar—H₄), δ8.23 (1H, d, J=8.1 Hz, Ar—H₅), δ8.23-8.32 (2H, m, Ar—H_(8,9)), δ8.39 (2H, d, J=8.1 Hz, Ar′—H_(2,6)), δ8.58 (2H, d, J=8.1 Hz, Ar′—H_(3,5)), δ10.15 (1H, br, —NH); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm): 117.81, 122.43, 123.62, 125.24, 125.88, 126.10, 127.92, 133.22, 133.36, 134.53, 143.08, 146.39, 146.77, 155.89, 172.18, 178.35, 179.40, 183.20 (CO), 185.56 (CO).

Embodiment 14 2-(4-Hydroxy-3-methoxyphenyl)-1H-anthra[1,2-d]imidazole-6,11-dione, No. 14

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in dimethylformamide (30 mL), and concentrated sulfuric acid (0.1 mL) is further added thereinto for catalyzation after vanillin (0.77 g, 5 mmol) is added thereinto. After mixing and reacting in room temperature for one hour, the reacted mixture is transferred into 200 mL of icy water. After filtering, the precipitate is collected and washed by hot alcohol, so as to obtain brown compound No. 14.

The compound No. 14 has the following characterstics: MW 370.0954 (C₂₂H₁₄N₂O₄); R_(f): 0.2 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3411(OH), 3411 (NH), 1664 (CO); EI-MS m/z: 369 (57%), 370 (M⁺, 100%) HRMS (ESI-TOF) m/z: calcd for C₂₂H₁₅N₂O₄ ⁺ [M+H]⁺: 370.1026, found: 370.1025; ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): δ3.91 (3H, s, —OCH₃), δ6.90 (1H, d, J=8.4 Hz, Ar′—H₅), δ7.81-7.88 (3H, m, Ar—H_(7,10), Ar′—H₂), δ7.92-7.96 (3H, m, Ar—H_(4,5), Ar′—H₆), δ7.99 (1H, s, —NH), δ8.11 (2H, td, J=Hz, Ar—H_(8,9)), δ9.78 (1H, br, —OH); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm): 56.57, 112.72, 116.37, 119.21, 119.65, 122.05, 122.95, 123.88, 126.81, 127.41, 128.42, 133.50, 133.64, 134.87, 135.09, 148.48, 150.87, 158.33, 182.85 (CO), 183.79 (CO).

Embodiment 15 2-p-Tolyl-1H-anthra[1,2-d]imidazole-6,11-dione, No. 15

All steps for manufacturing the to any compound No. 15 are identical with the steps of Embodiment 14, except that vanillin is substituted by ρ-tolualdehyde (0.7 ml, 5 mmol).

The compound No. 15 has the following characterstics: MW 338.1055 (C₂₂H₁₄N₂O₄); R_(f): 0.65 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3397(NH), 1659(CO); EI-MS m/z: 338(M⁺, 100%), 339(24%) HRMS (ESI-TOF) m/z: calcd for C₂₂H₁₅N₂O₄ ⁺ [M+H]⁺: 339.1128, found: 339.1128; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ2.46 (3H, s, Ar′—CH₃), δ7.37 (2H, d, J=8.1 Hz, Ar′—H_(3,5)), δ7.79 (2H, t, J=3.6 Hz, Ar—H_(7,10)), δ8.03 (2H, d, J=7.8 Hz, Ar′—H_(2,6)), δ8.08 (1H, d, J=8.4 Hz, Ar—H₅), δ8.21 (1H, d, J=8.4 Hz, Ar—H₄), δ8.24-8.34 (2H, m, Ar—H_(8,9)), δ11.21 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 21.58, 117.89, 121.96, 125.44, 125.75, 126.46, 127.00, 127.58, 128.43, 130.00, 133.20, 133.26, 133.72, 133.99, 134.38, 142.05, 149.50, 156.86, 182.60 (CO), 185.16 (CO).

Embodiment 16 2-(4-Bromophenyl)-1H-anthra[1,2-c]imidazole-6,11-dione, No. 16

All steps for manufacturing the red brown compound No. 16 are identical with the steps of Embodiment 14, except that vanillin is substituted by 4-bromobenzaldehyde (0.93 g, 5 mmol).

The compound No. 16 has the following characterstics: MW 402.0004 (C₂₁H₁₁N₂O₂Br); R_(f): 0.4 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3391(NH), 1658(CO); EI-MS m/z 402(M⁺, 100%), 404(97%), HRMS (ESI-TOF) m/z: calcd for C₂₁H₁₂N₂O₂Br⁺ [M+H]⁺: 403.0085, found: 403.0073 calcd for C₂₁H₁₀N₂O₂Br⁻ [M−H]⁻: 400.9939, found: 400.9923; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ7.72 (2H, d, J=8.7 Hz, Ar′—H_(3,5)), δ7.80-7.83 (2H, m, Ar—H_(7,10)), δ8.06 (2H, d, J=8.7 Hz, Ar′—H_(2,6)), δ8.13 (1H, d, J=8.4 Hz, Ar—H₄), δ8.25 (1H, d, J=8.4 Hz, Ar—H₅), δ8.27-8.36 (2H, m, Ar—H_(8,9)), δ11.29 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 122.18, 125.86, 126.11, 126.57, 127.64, 127.69, 128.50, 128.89, 132.61, 133.20, 133.35, 133.87, 134.01, 134.57, 149.40, 155.62, 182.63 (CO), 185.25 (CO).

Embodiment 17 2-(4-Cyanophenyl)-1H-anthra[1,2-d]imidazole-6,11-dione, No. 17

All steps for manufacturing the yellowish brown compound No. 17 are identical with the steps of Embodiment 14, except that vanillin is substituted by 4-cyanobenzaldehyde (0.67 g, 5 mmol).

The compound No. 17 has the following characterstics: MW 349.0851 (C₂₂H₁₁N₃O₂); R_(f): 0.65 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3341(NH), 2229(CN), 1667(CO); HRMS (ESI-TOF) m/z: calcd for C₂₂H₁₂N₃O₂ ⁺ [M+H]⁺: 350.0924, found: 350.0925; ¹H-NMR (300 MHz, CDCl₃) δ(ppm): δ7.80-7.85 (2H, m, Ar—H_(7,10)), δ8.06 (2H, d, J=8.1 Hz, δ8.18 (1H, d, J=8.4 Hz, Ar—H₅), δ8.27-8.32 (4H, m, Ar—H_(4,8,2′,6′)), δ8.35-8.38 (1H, m, Ar—H₉), δ11.46 (1H, s, —NH); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm): 114.71, 118.04, 118.52, 122.39, 126.39, 126.63, 127.57, 127.75, 129.45, 132.76, 133.04, 133.11, 133.34, 133.93, 133.99, 134.70, 149.17, 154.25, 182.56 (CO), 185.21 (CO).

Embodiment 18 2-(2,5-Dimethoxyphenyl)-1H-anthra[1,2-d]imidazole-6,11-dione, No. 18

All steps for manufacturing the red brown compound No. 18 are identical with the steps of Embodiment 14, except that vanillin is substituted by 2,5-dimethoxybenzaldehyde (0.89 g, 5 mmol).

The compound No. 18 has the following characterstics: MW 384.1110 (C₂₃H₁₆N₂O₄); R_(f): 0.4 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3417 (NH), 1660 (C═O), 1226 (C—O); HRMS (ESI-TOF) m/z: calcd for C₂₃H₁₇N₂O₄ ⁺ [M+H]⁺: 385.1183, found: 385.1181; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ3.93 (3H, s, Ar5′—OCH₃), δ4.21 (H, s, Ar₂—OCH₃), 67 7.09 (2H, d, J=1.2 Hz, Ar—H_(3′,4′)), δ7.79-7.82 (2H, m, Ar—H_(7,10)), δ8.13 (1H, d, J=8.1 Hz, Ar—H₅), δ8.13 (1H, s, Ar—H_(6′)), δ8.25 (1H, d, J=8.1 Hz, Ar—H₄), δ8.29-8.36 (2H, m, Ar—H_(8,9)), δ12.37 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 56.08, 56.69, 113.13, 113.36, 116.86, 118.14, 119.98, 121.92, 124.92, 126.46, 127.54, 129.92, 132.57, 133.43, 133.70, 134.06, 134.24, 135.39, 152.20, 154.23, 155.18, 182.82 (CO), 184.88 (CO).

Embodiment 19 2-(Benzo[d][1,3]dioxol-5-yl)-1H-anthra[1,2-d] imidazole-6,11-dione, No. 19)

All steps for manufacturing the red brown compound No. 19 are identical with the steps of Embodiment 14, except that vanillin is substituted by piperonal (0.77 g, 5 mmol).

The compound No. 19 has the following characterstics: MW 368.0797 (C₂₂H₁₂N₂O₄); R_(f): 0.45 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 3444(NH), 1670 (C═O), 1257(C—O), 1210(C—O); HRMS (ESI-TOF) m/z: calcd for C₂₂H₁₃N₂O₄ ⁺ [M+H]⁺: 369.0867, found: 369.0887; ¹H-NMR (300 MHz, CDCl₃) δ (ppm) δ6.11 (2H, s, —OCH₂O—), δ7.00 (1H, d, J=7.8 Hz, Ar—H_(5′)), δ7.67 (1H, s, Ar—H_(2′)), δ7.79-7.82 (2H, m, Ar—H_(7,10)), δ8.13 (1H, d, J=8.1 Hz, Ar—H₅), δ8.24 (1H, d, J=7.8 Hz, Ar—H_(6′)), δ8.25 (1H, d, J=8.1 Hz, Ar—H₄), δ8.29-8.36 (2H, m, Ar—H_(8,9)), δ11.18 (1H, s, —NH); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 101.93, 107.37, 108.96, 117.86, 121.83, 122.05, 122.78, 125.35, 126.52, 127.62, 128.40, 133.27, 133.43, 133.76, 134.08, 134.44, 148.71, 149.62, 150.56, 156.55, 182.66 (CO), 185.27 (CO).

Embodiment 20 Anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, No. 22

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in THF (30 mL), and triethylamine (3 mL) is further added thereinto for catalyzation after thionyl chloride (0.15 g, 20 mmol) is dripped thereinto. After mixing and reacting in room temperature for one hour, the reacted mixture is transferred into 200 mL of icy water. After filtering, the precipitate is collected and recrystallized by hot alcohol, so as to obtain yellow compound No. 22 with melting point of 227-228° C., and the production rate is 74%.

The compound No. 22 has the following characterstics: MW 266.0150 (C₁₄H₆N₂O₂S); R_(f): 0.8 (ethyl acetate:dichloromethane=1:4); IR (KBr) cm⁻¹: 1671 (CO); EI-MS m/z: 210(57%), 238(64%), 266 (M⁺, 100%), HRMS (ESI-TOF) m/z: calcd for C₁₄H₇N₂O₂S⁺ [M+H]⁺: 267.0223, found: 267.0226; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ7.84 (1H, dd, J=12.15, 6.9 Hz, Ar—H₇), δ7.85 (1H, dd, J=13.2, 7.5 Hz, Ar—H₁₀), δ8.33 (1H, dd, J=22.5, 7.2 Hz, Ar—H₈), δ8.33 (1H, dd, J=22.5, 7.2 Hz, Ar—H₉), δ8.41 (1H, d, J=9.3 Hz, Ar—H₅), δ8.56 (1H, d, J=9.3 Hz, Ar—H₄); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 125.07, 126.35, 126.99, 127.34, 127.61, 132.08, 133.47, 134.15, 134.75, 135.16, 150.93, 157.99, 181.97 (CO), 183.31 (CO).

Embodiment 21 2,2-Dimethyl-2,3-dihydro-1H-anthra[1,2-d] imidazole-6,11-dione, No. 20

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in dry acetone (100 mL), and concentrated sulfuric acid (0.1 mL) is further added thereinto. After mixing and reacting in room temperature for 48 hours, the reacted mixture is transferred into a potassium carbonate column. The product is collected and recrystallized by methanol, so as to obtain the purple compound 20, and the production rate is 31%. In the purification steps of the Embodiment 21, regular extraction method will reduce the production rate, and thus the basic column is used to remove the acid in the rough extract, so as to increase the production rate.

The compound No. 20 has the following characterstics: Melting point: 235-237□, MW 278.1055 (C₁₇H₁₄N₂O₂); R_(f): 0.5 (ethyl acetate: dichloromethane=1:4); IR (KBr) cm⁻¹: 3419(NH), 3239(NH), 1639 (CO); EI-MS m/z: 263(100%), 278(M⁺, 8.6%), HRMS (ESI-TOF) m/z: calcd for C₁₇H₁₅N₂O₂ ⁺ [M+H]⁺: 279.1128, found: 279.1133; ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): δ1.48 (6H, s, —CH₃), δ6.26 (1H, d, J=7.8 Hz, Ar—H₄), δ7.37 (1H, d, J=7.8 Hz, Ar—H₅), δ7.73-7.76 (m, 2H, Ar—H_(7,10)), δ8.05 (s, 1H, —NHC—), δ8.08-8.12 (m, 2H, Ar—H_(8,9)), δ8.79 (s, 1H, —CNH—); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm): 30.18, 81.70, 104.02, 108.04, 120.99, 123.54, 126.32, 127.07, 133.41, 133.54, 134.79, 135.46, 143.05, 148.12, 179.89 (CO), 182.47 (CO).

Embodiment 22 2-Methyl-2-phenyl-2,3-dihydro-1H-anthra[1,2-d]imidazole-6,11-dione, No. 21

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in N,N-dimethylformamide (30 mL), and concentrated sulfuric acid (0.1 mL) is further added thereinto after acetophenone (0.5 ml, 6 mmol) is added thereinto. After mixing and reacting in room temperature for 72 hours, the reacted mixture is transferred into icy water (200 mL) for precipitation. The precipitate is collected and recrystallized by hot alcohol, so as to obtain the black compound 21, and the production rate is 28%.

The compound No. 21 has the following characterstics: Melting point: 368-371□, MW 340.1212 (C₂₂H₁₆N₂O₂); R_(f): 0.8 (ethyl acetate: dichloromethane=1:4); IR (KBr) cm⁻¹: 3348(NH), 1671 (CO); HRMS (ESI-TOF) m/z: calcd for C₂₂H₁₇N₂O₂ ⁺ [M+H]⁺: 341.1284, found: 341.1033; ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): δ1.22 (3H, s, —CH₃), δ7.56-7.62 (3H, m, Ar′—H_(2,4,6)), δ7.90-7.94 (2H, m, Ar—H_(7,10)), δ8.08 (1H, d, J=8.1 Hz, Ar—H₅), δ8.22 (1H, d, J=8.1 Hz, Ar—H₄), δ8.18-8.22 (2H, m, Ar′—H_(3,5)), δ8.40-8.42 (2H, m, Ar—H_(8,9)); and ¹³C-NMR (75 MHz, DMSO) δ (ppm): 28.79, 83.56, 103.62, 109.74, 119.13, 121.35, 124.03, 126.20, 1267.76, 128.32, 128.77, 131.31, 132.99, 134.30, 134.45, 143.05, 157.25, 182.60 (CO), 182.89 (CO).

Embodiment 23 2,3-dimethylnaphtho[2,3-f]quinoxaline-7,12-dione, No. 24

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in N,N-dimethylformamide (30 mL), and concentrated sulfuric acid (0.1 mL) is further added thereinto after methyl vinyl ketone (0.36 g, 5 mmol) is added thereinto. After mixing and reacting in room temperature for 72 hours, the reacted mixture is transferred into icy water (200 mL) for precipitation. The precipitate is collected and recrystallized by hot alcohol, so as to obtain the black compound 24, and the production rate is 25%.

The compound No. 24 has the following characterstics: Melting point >400□, MW 288.0899 (C₁₈H₁₂N₂O₂); R_(f): 0.6 (ethyl acetate: dichloromethane=1:4); IR (KBr) cm⁻¹: 1671 (CO); HRMS (ESI-TOF) m/z: calcd for C₁₈H₁₃N₂O₂ ⁺ [M+H]⁺: 289.0988, found: 289.0970; ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): δ2.72 (3H, s, —CH₃), δ2.88 (3H, s, —CH₃), δ7.91-7.94 (2H, m, Ar—H_(8,11)), δ8.07 (1H, d, J=8.4 Hz, Ar—H₅), δ8.16 (1H, d, J=8.4 Hz, Ar—H₄), δ8.19-8.21 (2H, m, Ar—H_(9,10)); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm): 14.91, 30.74, 120.19, 125.46, 126.21, 126.26, 127.16, 128.18, 128.87, 133.01, 133.10, 134.19, 134.27, 134.42, 158.87, 162.28, 182.49 (CO), 183.37 (CO).

Embodiment 24 Naphtho[2,3-f]quinoxaline-7,12-dione, No. 25

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in N,N-dimethylformamide (30 mL), and 40% glyoxal (0.8 g, 5 mml) in EtOH (50 mL) is added thereinto. After reverse flow for 16 hours, the water is evaporated out, and the reacted mixture is transferred into icy water (200 mL) for precipitation. The precipitate is collected and washed by hot alcohol and dichloromethane repeatedly, so as to obtain the black compound 25, and the production rate is 23%.

The compound No. 25 has the following characterstics: Melting point: 270-272 □, MW 260.0586 (C₁₆H₈N₂O₂); R_(f): 0.45 (ethyl acetate: dichloromethane=1:4); IR (KBr) cm⁻¹: 3413(NH), 3365(NH), 1626 (CO); EI-MS m/z: 150(54%), 238(73%), 260(M⁺, 100%); HRMS (ESI-TOF) m/z: calcd for C₁₆H₉N₂O₂ ⁺ [M+H]⁺: 261.0659, found: 261.0663; ¹H-NMR (300 MHz, CDCl₃) δ (ppm): δ7.82-7.87 (2H, m, Ar—H_(8,11)), δ8.29-8.36 (2H, m, Ar—H_(9,10)), δ8.48 (1H, d, J=8.7 Hz, Ar—H₅), δ8.72 (1H, d, J=8.7 Hz, Ar—H₆), δ8.99 (1H, d, J=1.5 Hz, —N═CH—), δ9.25 (1H, d, J=1.5 Hz, —CH═N—); and ¹³C-NMR (75 MHz, CDCl₃) δ (ppm): 126.72, 127.05, 127.46, 130.05, 131.98, 133.77, 134.76, 135.18, 135.88, 135.93, 136.03, 145.42, 146.40, 147.77, 183.21 (CO), 183.61 (CO).

Embodiment 25 Naphtho[2,3-f]quinoxaline-2,3,7,12(1H,4H)-tetraone, No. 26

1,2-Diaminoanthraquinone (1.19 g, 5 mmol) is dissolved in N,N-dimethylformamide (30 mL), and oxalic acid (0.46 g, 5 mmol) and concentrated sulfuric acid (0.1 mL) is added thereinto. After reverse flow for 16 hours, the reacted mixture is transferred into icy water (200 mL) for precipitation. The precipitate is collected and washed by hot alcohol and, so as to obtain the black compound 26, and the production rate is 30%.

The compound No. 25 has the following characterstics: Melting point: 245-246 □, MW 292.0484 (C₁₆H₈N₂O₄); R_(f): 0.25 (ethyl acetate: dichloromethane=1:4); IR (KBr) cm⁻¹: 1710 (CO), 1671 (CONH); EI-MS m/z: 248(100%), 292(M⁺) HRMS (ESI-TOF) m/z: calcd for C₁₆H₉N₂O₄ ⁺ [M+H]⁺: 293.0557, found: 293.0568: ¹H-NMR (300 MHz, DMSO-d₆) δ (ppm): δ7.71 (1H, d, J=8.0 Hz, Ar—H₅), δ7.93-7.98 (2H, m, Ar—H_(8,11)), δ8.04 (1H, d, J=8.0 Hz, Ar—H₆), δ8.17-8.24 (2H, m, Ar—H_(9,10)), δ8.99 (1H, d, J=1.5 Hz, —NH—), δ9.25 (1H, d, J=1.5 Hz, —NH—); and ¹³C-NMR (75 MHz, DMSO-d₆) δ (ppm); 118.08, 120.52, 122.87, 126.26, 126.34, 126.78, 127.71, 128.17, 129.58, 134.48, 134.55, 135.07, 154.64 (NHCO), 154.73 (NHCO), 180.08 (CO), 181.07 (CO).

The chemical formula, production rates and melting points of the above-mentioned heteroannelated anthraquinone derivatives of series A are illustrated in Table 1, and the chemical formula, production rates and melting points of the above-mentioned heteroannelated anthraquinone derivatives of series B, C and D are described in the embodiments, respectively.

TABLE 1

Compound Melting point Production No. R₁ (□) Rate (%) 2 —CH₃ >400 67 3 —CH₂Cl 272-273 86 4 —CH₂CH₃ 193-194 39 5 —CH(CH₃)₂ 199-200 41 6 —(CH₂)₃CH₃ 192-193 −36 7 —CH(CH₃)CH₂CH₃ 118-119 40 8 —CH(CH₃)₃ 209-210 37 9 —(CH₂)₆CH₃ 85-87 38 10 —CH═CHCH₂CH₃ 117-119 33 11 —C₆H₅ 232-233 74 12 —C₆H₄-p-N(CH₃)₂ 239-241 79 13 —C₆H₄-p-NO₂ 342-343 89 14 —C₆H₃-p-OH-m-OCH₃ 230-231 47 15 —C₆H₄-p-CH₃ 256-257 76 16 —C₆H₄-p-Br 302-303 75 17 —C₆H₄-p-CN 353-354 77 18 —C₆H₃-o,m-(OCH₃)₂ 251-252 74 19 3,4-benzdioxole 300-301 81

Telomeric repeat amplification protocol (TRAP) is employed to detect the effect of the heteroannelated anthraquinone derivatives synthesized in the present invention for inhibiting the telomerase activity. In the first stage of this method, the telemerase is used to prolong the oligonucleotide with telomere sequence in the conditions of 90° C. for 10 minutes, 72° C. for 3 minutes, 50° C. for 60 seconds and 94° C. for 30 seconds (TSG4 primer: 5′-GGG ATT GGG ATT GGG ATT GGG TT-3′) In the second stage, different compounds are added into the telomerase reacted product to further replicate the telomere product by PCR (CX primer: 5′-CCCTTA CCCTTA CCCTTA CCCTAA-3′). When the compound inhibits the telomerase activity, the replication reaction can not be resumed. The PCR conditions includes 39 cycles of PCR reaction in 50° C. for 30 seconds, 72° C. for 60 seconds for 39 PCR cycles, followed by one cycle of reaction in 94° C. for 30 seconds, 50° C. for 30 seconds, 72° C. for 30 seconds and 72° C. for 1 minute, and the reaction is ended in 4° C. The PCR product is analyzed by electrophoresis using 10% acrylamide gel. In the electrophoresis results, the positive control (P) is sterile water (dddH₂O), and the negative control (N) is 5 μl 0.1 mg/mL RNase A (CLONTECH). The positive control (P) produces lots of telomere fragment, while the negative control (N) does not. The compounds provided by the present invention inhibit the telomerase activity by stabilizing G-quadruplex structures and blocking the interaction between telomerase and telomere, or directly inhibit the telomerase activity, so as to inhibit the prolongation of telomere. It is found in the present experiments that the Embodiments A4 and A5 have better inhibition effects.

In addition, it is found in the in vitro experiments performed by the development therapeutics program of US cancer research center that the heteroannelated anthraquinone derivatives synthesized in the present invention have various inhibition effects on different cancer cell lines at 1.0×10⁻⁵ molal concentration (M) as shown in Table 2. For example, the Embodiment A2 of the present invention inhibits the growth of breast cancer cell HS578T, and the Embodiment B1 has overall and the most obvious inhibition on different cancer cells. Therefore, the heteroannelated anthraquinone derivatives synthesized in the present invention are potential drugs for inhibiting cancer cells.

TABLE 2 No. 22 No. 4 No. 20 No. 25 No. 26 Non-small cell lung cancer cell HOP-62 −100.00 97.73 XXX XXX XXX HOP-92 XXX 41.43 5.10 XXX −15.08 Colorectal cancer cell HCC-2998 −50.00 67.67 136.96 −7.15 77.59 Breast cancer cell HS 578T −7.40 −18.58 XXX XXX XXX MCF7 −50.74 69.82 83.58 39.68 85.17 MDA-MB-435 −87.88 84.39 124.56 102.03 144.42 MDA-MB-468 −73.17 XXX 77.25 75.28 38.35 T-47D −45.52 63.05 82.96 85.19 87.10 Ovary cancer cell IGROV1 −88.34 XXX −2.80 3.44 13.36 OVCAR-4 −94.43 48.81 80.14 94.22 103.31 Blood cancer cell MOLT-4 −40.09 64.17 116.41 22.91 121.52 Kidney cancer cell ACHN −94.31 24.97 50.17 46.52 81.33 SN12C −73.27 68.53 91.98 64.65 94.07 UO-31 −79.30 23.94 30.65 51.45 61.43 Skin cancer cell LOX IMV1 −50.6 39.98 61.88 44.18 96.94 MALME-3M −71.54 56.94 155.47 180.88 149.83 SK-MEL-2 −73.16 40.07 8.04 6.66 21.96 UACC-257 −83.07 39.69 118.22 91.06 118.21 UACC-62 −82.32 51.35 67.58 90.47 95.25 CNS cancer cell SF-539 −47.11 83.16 93.56 40.72 101.16 U251 −89.26 60.13 87.84 63.47 95.92 Mean 2.68 58.42 80.41 69.36 100.83 Delta 102.68 77.00 83.21 76.51 115.91 Range 230.09 120.88 158.27 188.03 289.23 xxx: not detected

The detailed in-vitro testing results of dose response of the Compound No. 22 obtained from National Cancer Institute Developmental Therapeutics Program are shown in Tables 3-1 to 3-9.

The detailed in-vitro testing results of dose response of the Compound No. 4 obtained from National Cancer Institute Developmental Therapeutics Program are shown in Tables 4-1 to 4-9.

The detailed in-vitro testing results of dose response of the Compound No. 25 obtained from National Cancer Institute Developmental Therapeutics Program are shown in Tables 5-1 to 5-9.

TABLE 3-1 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Leukemia Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 CCRF-CEM 0.445 1.624 1.589 1.503 1.323 0.472 0.470 97 90 74 2 2 2.18E−6 >1.00E−4 >1.00E−4 HL-60(TB) 0.744 2.175 2.214 2.209 2.079 0.461 0.421 103 102 93 −38 −43 2.14E−6 5.13E−6 >1.00E−4 K-562 0.180 1.220 1.232 1.174 1.038 0.375 0.165 101 96 83 19 −8 3.23E−6 4.92E−5 >1.00E−4 MOLT-4 0.455 1.447 1.444 1.462 1.199 0.274 0.280 97 99 73 −40 −38 1.59E−6 4.43E−6 >1.00E−4 RPMI-8226 0.654 1.899 1.899 1.820 1.418 0.653 0.523 100 94 61 . −20 1.53E−6 9.91E−6 >1.00E−4 SR 0.167 0.676 0.718 0.738 0.669 0.374 0.278 108 112 99 41 −22 6.89E−6 >1.00E−4 >1.00E−4

TABLE 3-2 Panel/Cell Line Log10 Concentration Non-Small Cell Time Mean Optical Densities Percent Growth Lung Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 A549/ATCC 0.110 0.550 0.566 0.518 0.513 0.081 0.091 104 93 92 −27 −18 2.25E−6 5.94E−6 >1.00E−4 EKVX 0.652 1.960 1.914 1.813 1.745 0.554 0.251 96 89 84 −15 −62 2.19E−6 7.03E−6 5.65E−5 HOP-62 0.342 1.187 1.242 1.242 1.243 0.380 0.175 107 107 107 4 −49 3.59E−6 1.21E−5 >1.00E−4 HOP-92 0.770 1.201 1.179 1.150 1.174 0.765 0.560 95 88 94 −1 −27 2.91E−6 9.84E−6 >1.00E−4 NCI-H226 1.003 1.740 1.718 1.701 1.556 1.467 0.956 97 95 75 63 −5 1.56E−5 8.53E−5 >1.00E−4 NCI-H23 0.418 1.199 1.209 1.125 0.775 0.265 0.271 101 91 46 −37 −35 8.02E−7 3.59E−6 >1.00E−4 NCI-H322M 0.347 0.840 0.856 0.922 0.940 0.890 0.555 103 116 120 110 42 7.64E−5 >1.00E−4 >1.00E−4 NCI-H460 0.245 1.818 1.818 1.767 1.614 0.116 0.104 100 97 87 −53 −58 1.84E−6 4.19E−6 9.54E−6 NCI-H522 0.541 2.032 2.079 2.073 1.887 0.634 0.441 103 103 90 6 −18 3.01E−6 1.78E−5 >1.00E−4

TABLE 3-3 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Colon Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 COLO 205 0.199 0.969 0.927 0.872 0.957 0.069 0.057 95 87 98 −66 −71 1.97E−6 3.98E−6 8.04E−6 HCC-2998 0.268 0.572 0.599 0.581 0.588 0.098 0.081 109 103 105 −63 −70 2.12E−6 4.20E−6 8.32E−6 HCT-116 0.138 0.938 0.927 0.912 0.863 0.145 0.095 99 97 91 1 −31 2.84E−6 1.06E−5 >1.00E−4 HCT-15 0.285 1.440 1.554 1.485 1.323 0.254 0.138 110 104 90 −11 −52 2.49E−6 7.80E−6 9.06E−5 HT29 0.231 1.387 1.432 1.444 1.403 0.195 0.108 104 105 101 −16 −53 2.75E−6 7.36E−6 8.10E−5 KM12 0.217 0.841 0.884 0.889 0.861 0.567 0.103 107 108 103 56 −53 1.14E−5 3.28E−5 9.48E−5 SW-620 0.175 1.174 1.231 1.201 1.240 0.633 0.056 106 103 107 46 −68 8.55E−6 2.52E−5 6.92E−5

TABLE 3-4 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth CNS Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 SF-268 0.357 0.951 0.959 0.938 0.893 0.459 0.193 101 98 90 17 −46 3.55E−6 1.87E−5 >1.00E−4 SF-295 0.415 1.524 1.550 1.579 1.527 0.404 0.202 102 105 100 −3 −51 3.08E−6 9.40E−6 9.39E−5 SF-539 0.574 1.690 1.578 1.517 1.499 0.006 0.012 90 84 83 −99 −98 1.52E−6 2.86E−6 5.38E−6 SNB-19 0.464 1.328 1.349 1.339 1.330 0.067 0.008 102 101 100 −86 −98 1.86E−6 3.46E−6 6.43E−6 SNB-75 0.640 1.050 0.950 0.911 0.957 −0.004 −0.009 76 66 77 −100 −100 1.42E−6 2.73E−6 5.22E−6 U251 0.220 1.137 1.194 1.177 0.939 0.086 0.082 106 104 78 −61 −63 1.60E−6 3.65E−6 8.32E−6

TABLE 3-5 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Melanoma Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 LOX IMVI 0.363 2.033 2.046 2.006 1.219 0.212 0.244 101 98 51 −42 −33 1.03E−6 3.56E−6 >1.00E−4 MALME-3M 0.229 0.481 0.487 0.520 0.512 0.107 0.065 102 115 112 −53 −72 2.37E−6 4.76E−6 9.55E−6 M14 0.339 1.395 1.398 1.394 1.411 0.232 0.199 100 100 102 −32 −41 2.44E−6 5.78E−6 >1.00E−4 SK-MEL-2 0.284 0.761 0.810 0.806 0.731 0.221 0.194 110 109 94 −22 −32 2.38E−6 6.42E−6 >1.00E−4 SK-MEL-28 0.300 1.110 1.135 1.161 1.165 0.703 0.023 103 106 107 50 −93 9.88E−6 2.24E−5 5.03E−5 SK-MEL-5 0.540 2.145 2.107 1.896 1.477 −0.009 −0.002 98 85 58 −100 −100 1.13E−6 2.34E−6 4.83E−6 UACC-257 0.493 0.980 0.962 0.986 0.870 0.083 0.047 96 101 77 −83 −91 1.48E−6 3.03E−6 6.21E−6 UACC-62 0.431 1.918 1.751 1.787 1.798 0.331 0.214 89 91 92 −23 −50 2.31E−6 6.29E−6 9.62E−6

TABLE 3-6 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Ovarian Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 OVCAR-3 0.305 0.775 0.852 0.821 0.710 0.216 0.075 116 110 86 −29 −75 2.06E−6 5.59E−6 2.82E−5 OVCAR-4 0.363 0.880 0.916 0.850 0.531 −0.015 −0.014 107 94 32 −100 −100 5.20E−7 1.76E−6 4.19E−6 OVCAR-5 0.446 0.930 0.924 0.903 0.953 0.192 0.187 99 94 105 −57 −58 2.18E−6 4.44E−6 9.06E−6 OVCAR-8 0.299 1.154 1.200 1.171 0.695 0.169 0.185 105 102 46 −43 −38 8.59E−7 3.28E−6 >1.00E−4 SK-OV-3 0.530 1.224 1.239 1.154 1.150 0.414 0.015 102 90 89 −22 −97 2.26E−6 6.35E−6 2.36E−5

TABLE 3-7 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Renal Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 786-0 0.450 1.828 1.894 1.916 2.049 0.517 0.130 105 106 116 5 −71 3.93E−6 1.16E−5 5.27E−5 A498 0.605 1.481 1.527 1.518 1.449 1.479 1.340 105 104 96 100 84 >1.00E−4 >1.00E−4 >1.00E−4 ACHN 0.355 1.317 1.389 1.452 1.220 0.063 0.218 107 114 90 −82 −39 1.71E−6 3.33E−6 . CAKI-1 0.294 0.870 0.813 0.844 0.798 0.226 0.099 90 95 88 −23 −66 2.18E−6 6.16E−6 4.15E−5 SN12C 0.304 1.076 1.007 1.097 0.948 0.284 0.199 91 103 83 −7 −35 2.35E−6 8.42E−6 >1.00E−4 TK-10 0.362 0.792 0.865 0.935 0.983 0.868 0.337 117 133 144 118 −7 3.49E−5 8.80E−5 >1.00E−4 UO-31 0.147 0.498 0.539 0.562 0.499 0.041 0.050 111 118 100 −72 −66 1.95E−6 3.81E−6 7.41E−6

TABLE 3-8 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Prostate Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 PC-3 0.372 1.158 1.128 1.096 1.050 0.459 0.402 96 92 86 11 4 3.03E−6 >1.00E−4 >1.00E−4 DU-145 0.230 0.704 0.750 0.772 0.752 0.425 −0.002 110 114 110 41 −100 7.41E−6 1.95E−5 4.42E−5

TABLE 3-9 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Breast Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 MCF7 0.282 1.325 1.202 1.081 0.929 0.101 0.104 88 77 62 −64 −63 1.24E−6 3.10E−6 7.72E−6 NCI/ADR-RES 0.436 1.282 1.343 1.296 0.608 0.395 0.363 107 102 20 −10 −17 4.32E−7 4.80E−6 >1.00E−4 MDA-MB-231/ATCC 0.478 1.197 1.226 1.100 1.063 0.510 0.525 104 87 81 4 6 2.56E−6 >1.00E−4 >1.00E−4 HS 578T 0.413 1.287 1.362 1.410 1.289 0.663 0.595 109 114 100 29 21 5.03E−6 >1.00E−4 >1.00E−4 MDA-MB-435 0.280 1.351 1.350 1.373 1.160 0.190 0.137 100 102 82 −32 −51 1.91E−6 5.23E−6 8.78E−5 BT-549 0.254 0.524 0.503 0.529 0.594 0.426 0.122 92 102 126 64 −52 1.31E−5 3.55E−5 9.62E−5 T-47D 0.377 0.816 0.775 0.763 0.473 0.156 0.150 91 88 22 −59 −60 3.75E−7 1.87E−6 7.79E−6 MDA-MB-468 2.275 3.124 3.096 3.134 3.152 0.022 0.031 97 101 103 −99 −99 1.83E−6 3.24E−6 5.72E−6

TABLE 4-1 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Leukemia Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 CCRF-CEM 0.321 1.468 1.505 1.400 1.407 0.910 0.488 103 94 95 51 15 1.09E−5 >1.00E−4 >1.00E−4 HL-60(TB) 0.691 1.628 1.626 1.630 1.639 1.092 0.873 100 100 101 43 19 7.53E−6 >1.00E−4 >1.00E−4 K-562 0.269 1.578 1.498 1.469 1.412 1.097 0.903 94 92 87 63 48 7.83E−5 >1.00E−4 >1.00E−4 MOLT-4 0.734 2.108 2.076 2.057 2.015 1.402 0.726 98 96 93 49 −1 9.31E−6 9.51E−5 >1.00E−4 RPMI-8226 0.443 1.284 1.259 1.121 1.060 0.547 0.390 97 81 73 12 −12 2.42E−6 3.21E−5 >1.00E−4

TABLE 4-2 Panel/Cell Line Log10 Concentration Non-Small Cell Time Mean Optical Densities Percent Growth Lung Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 A549/ATCC 0.193 0.895 0.832 0.892 0.876 0.614 0.315 91 100 97 60 17 1.71E−5 >1.00E−4 >1.00E−4 EKVX 0.897 1.986 1.856 1.792 1.540 1.059 0.894 88 82 59 15 . 1.60E−6 9.43E−5 >1.00E−4 HOP-62 0.474 1.375 1.283 1.318 1.254 1.127 0.814 90 94 87 72 38 4.42E−5 >1.00E−4 >1.00E−4 HOP-92 0.892 1.397 1.360 1.297 1.214 1.134 1.010 93 80 64 48 23 7.38E−6 >1.00E−4 >1.00E−4 NCI-H226 0.817 1.747 1.612 1.642 1.608 1.404 1.022 85 89 85 63 22 2.08E−5 >1.00E−4 >1.00E−4 NCI-H23 0.485 1.638 1.547 1.500 1.333 1.051 0.732 92 88 74 49 21 9.17E−6 >1.00E−4 >1.00E−4 NCI-H322M 0.721 1.844 1.757 1.746 1.643 1.177 0.976 92 91 82 41 23 5.94E−6 >1.00E−4 >1.00E−4 NCI-H460 0.233 1.933 1.666 1.630 1.494 0.651 0.266 84 82 74 25 2 3.07E−6 >1.00E−4 >1.00E−4 NCI-H522 0.713 2.605 2.403 2.370 2.360 1.735 1.328 89 88 87 54 32 1.54E−5 >1.00E−4 >1.00E−4

TABLE 4-3 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Colon Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 COLO 205 0.213 1.012 0.960 0.958 0.891 0.544 0.284 93 93 85 41 9 6.36E−6 >1.00E−4 >1.00E−4 HCC-2998 0.660 2.134 1.963 2.044 1.983 1.527 0.988 88 94 90 59 22 1.74E−5 >1.00E−4 >1.00E−4 HCT-116 0.248 2.129 1.969 2.043 1.716 1.044 0.450 92 95 78 42 11 6.10E−6 >1.00E−4 >1.00E−4 HCT-15 0.248 1.514 1.391 1.422 1.121 0.588 0.348 90 93 69 27 8 2.82E−6 >1.00E−4 >1.00E−4 HT29 0.151 0.999 0.951 0.998 0.893 0.557 0.241 94 100 88 48 11 8.84E−6 >1.00E−4 >1.00E−4 KM12 0.268 1.092 1.072 1.040 1.003 0.625 0.373 98 94 89 43 13 7.15E−6 >1.00E−4 >1.00E−4 SW-620 0.150 0.998 0.991 0.968 0.902 0.480 0.202 99 96 89 39 6 5.97E−6 >1.00E−4 >1.00E−4

TABLE 4-4 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth CNS Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 SF-268 0.319 1.084 0.986 1.053 0.990 0.758 0.530 87 96 88 57 28 1.77E−5 >1.00E−4 >1.00E−4 SF-295 0.695 1.929 1.785 1.806 1.549 1.127 0.812 88 90 69 35 9 3.65E−6 >1.00E−4 >1.00E−4 SF-539 0.639 1.878 1.642 1.666 1.631 1.204 0.798 81 83 80 46 13 7.46E−6 >1.00E−4 >1.00E−4 SNB-19 0.656 1.341 1.229 1.299 1.289 1.073 0.921 84 94 92 61 39 3.09E−5 >1.00E−4 >1.00E−4 SNB-75 0.661 1.282 1.068 1.070 0.965 0.916 0.770 66 66 49 41 17 8.72E−7 >1.00E−4 >1.00E−4 U251 0.280 1.443 1.369 1.393 1.260 0.854 0.597 94 96 84 49 27 9.58E−6 >1.00E−4 >1.00E−4

TABLE 4-5 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Melanoma Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 LOX IMVI 0.316 2.231 2.245 2.058 1.903 0.956 0.508 101 91 83 33 10 4.61E−6 >1.00E−4 >1.00E−4 MALME-3M 0.694 1.247 1.174 1.161 1.153 0.835 0.683 87 84 83 26 −2 3.75E−6 8.69E−5 >1.00E−4 M14 0.435 1.796 1.627 1.731 1.500 1.119 0.776 88 95 78 50 25 1.02E−5 >1.00E−4 >1.00E−4 SK-MEL-28 0.239 0.861 0.794 0.762 0.730 0.537 0.211 89 84 79 48 −12 8.58E−6 6.36E−5 >1.00E−4 SK-MEL-5 0.639 2.089 1.284 1.249 1.501 0.607 0.515 44 42 59 −5 −19 . 8.36E−6 >1.00E−4 UACC-257 0.437 0.825 0.763 0.761 0.808 0.694 0.506 84 84 96 66 18 2.16E−5 >1.00E−4 >1.00E−4 UACC-62 0.639 2.092 1.844 1.978 1.874 1.231 1.015 83 92 85 41 26 6.18E−6 >1.00E−4 >1.00E−4

TABLE 4-6 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Ovarian Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 IGROV1 0.518 1.681 1.555 1.537 1.174 0.583 0.421 89 88 56 6 −19 1.34E−6 1.69E−5 >1.00E−4 OVCAR-3 0.283 0.746 0.745 0.773 0.713 0.549 0.319 100 106 93 57 8 1.41E−5 >1.00E−4 >1.00E−4 OVCAR-4 0.565 1.740 1.719 1.694 1.535 0.999 0.745 98 96 83 37 15 5.18E−6 >1.00E−4 >1.00E−4 OVCAR-5 0.395 0.931 0.865 0.884 0.900 0.852 0.637 88 91 94 85 45 7.57E−5 >1.00E−4 >1.00E−4 OVCAR-8 0.228 0.904 0.881 0.841 0.847 0.623 0.393 96 91 92 58 24 1.77E−5 >1.00E−4 >1.00E−4 SK-OV-3 0.566 1.432 1.392 1.359 1.223 0.673 0.687 95 92 76 12 14 2.55E−6 >1.00E−4 >1.00E−4

TABLE 4-7 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Renal Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 786-0 0.664 2.228 2.288 2.259 2.143 1.725 1.264 104 102 95 68 38 4.02E−5 >1.00E−4 >1.00E−4 A498 0.564 1.224 1.202 1.221 1.065 0.793 0.453 94 97 74 34 −20 3.89E−6 4.27E−5 >1.00E−4 ACHN 0.385 1.455 1.393 1.299 1.047 0.537 0.366 94 85 62 14 −5 1.77E−6 5.46E−5 >1.00E−4 CAKI-1 0.547 1.711 1.680 1.610 1.430 0.780 0.654 97 91 76 20 9 2.90E−6 >1.00E−4 >1.00E−4 SN12C 0.617 1.996 1.639 1.719 1.640 1.247 0.872 74 80 74 46 18 7.05E−6 >1.00E−4 >1.00E−4 TK-10 0.612 1.245 1.212 1.327 1.088 0.856 0.633 95 113 75 39 3 4.88E−6 >1.00E−4 >1.00E−4 UO-31 0.517 1.634 1.496 1.444 1.268 0.680 0.518 88 83 67 15 . 2.12E−6 >1.00E−4 >1.00E−4

TABLE 4-8 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Prostate Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 PC-3 0.306 1.233 1.197 1.233 1.170 0.807 0.572 96 100 93 54 29 1.44E−5 >1.00E−4 >1.00E−4 DU-145 0.226 0.724 0.713 0.713 0.666 0.411 0.344 98 98 88 37 24 5.62E−6 >1.00E−4 >1.00E−4

TABLE 4-9 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Breast Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 MCF7 0.249 1.082 0.960 0.880 0.697 0.556 0.240 85 76 54 37 −4 1.68E−6 8.14E−5 >1.00E−4 NCI/ADR-RES 0.461 1.540 1.483 1.524 1.421 1.010 0.530 95 99 89 51 6 1.05E−5 >1.00E−4 >1.00E−4 MDA-MB-231/ATCC 0.453 1.133 1.121 1.097 1.063 0.820 0.700 98 95 90 54 36 1.66E−5 >1.00E−4 >1.00E−4 HS 578T 0.296 0.704 0.734 0.736 0.526 0.393 0.202 107 108 56 24 −32 1.56E−6 2.67E−5 >1.00E−4 MDA-MB-435 0.515 1.859 1.815 1.744 1.748 1.404 1.019 97 91 92 66 37 3.65E−5 >1.00E−4 >1.00E−4 BT-549 1.015 2.001 2.009 2.006 1.951 1.606 1.166 101 100 95 60 15 1.67E−5 >1.00E−4 >1.00E−4 T-47D 0.415 0.852 0.876 0.824 0.755 0.554 0.459 105 94 78 32 10 4.00E−6 >1.00E−4 >1.00E−4 MDA-MB-468 0.494 1.038 0.944 0.977 0.923 0.654 0.458 83 89 79 29 −7 3.83E−6 6.33E−5 >1.00E−4

TABLE 5-1 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Leukemia Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 CCRF-CEM 0.230 0.806 0.751 0.755 0.622 0.358 0.344 90 91 68 22 20 2.46E−6 >1.00E−4 >1.00E−4 HL-60(TB) 0.336 0.640 0.587 0.540 0.478 0.347 0.153 83 67 47 3 −54 6.77E−7 1.15E−5 8.37E−5 K-562 0.086 0.900 0.851 0.422 0.332 0.225 0.166 94 41 30 17 10 6.83E−8 >1.00E−4 >1.00E−4 MOLT-4 0.273 1.048 0.959 0.900 0.830 0.529 0.302 89 81 72 33 4 3.65E−6 >1.00E−4 >1.00E−4 RPMI-8226 0.429 1.331 1.245 1.161 0.926 0.702 0.535 90 81 55 30 12 1.61E−6 >1.00E−4 >1.00E−4

TABLE 5-2 Panel/Cell Line Log10 Concentration Non-Small Cell Time Mean Optical Densities Percent Growth Lung Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 A549/ATCC 0.551 1.857 1.771 1.792 1.552 1.022 0.594 93 95 77 36 3 4.53E−6 >1.00E−4 >1.00E−4 EKVX 0.439 1.025 1.032 0.960 0.904 0.584 0.421 101 89 79 25 −4 3.45E−6 7.21E−5 >1.00E−4 HOP-62 0.233 0.934 0.879 0.811 0.799 0.512 0.255 92 82 81 40 3 5.64E−6 >1.00E−4 >1.00E−4 HOP-92 0.785 1.360 1.334 1.260 1.231 1.206 0.829 95 83 78 73 8 2.25E−5 >1.00E−4 >1.00E−4 NCI-H226 0.780 1.765 1.631 1.577 1.497 1.415 0.769 86 81 73 64 −1 1.66E−5 9.52E−5 >1.00E−4 NCI-H23 0.452 1.356 1.281 1.242 1.213 0.950 0.407 92 87 84 55 −10 1.20E−5 7.03E−5 >1.00E−4 NCI-H322M 0.310 0.751 0.736 0.709 0.722 0.592 0.307 96 90 93 64 −1 1.63E−5 9.61E−5 >1.00E−4 NCI-H460 0.229 1.901 1.869 1.815 1.309 0.507 0.179 98 95 65 17 −22 2.01E−6 2.69E−5 >1.00E−4 NCI-H522 0.336 1.040 0.966 0.942 0.906 0.579 0.226 89 86 81 35 −33 4.64E−6 3.25E−5 >1.00E−4

TABLE 5-3 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Colon Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 COLO 205 0.211 0.782 0.739 0.704 0.634 0.376 0.138 92 86 74 29 −35 3.40E−6 2.84E−5 >1.00E−4 HCC-2998 0.326 1.161 1.135 1.113 0.759 0.658 0.315 97 94 52 40 −3 1.40E−6 8.35E−5 >1.00E−4 HCT-116 0.142 1.101 1.060 1.089 1.018 0.666 0.175 96 99 91 55 3 1.23E−5 >1.00E−4 >1.00E−4 HCT-15 0.274 1.667 1.502 1.449 1.343 0.784 0.266 88 84 77 37 −3 4.63E−6 8.43E−5 >1.00E−4 HT29 0.174 1.186 1.176 1.131 0.925 0.636 0.184 99 95 74 46 1 7.01E−6 >1.00E−4 >1.00E−4 KM12 0.224 0.967 0.884 0.896 0.786 0.522 0.185 89 90 76 40 −18 5.26E−6 4.95E−5 >1.00E−4 SW-620 0.159 1.008 0.960 0.901 0.649 0.369 0.118 94 87 58 25 −26 1.71E−6 3.08E−5 >1.00E−4

TABLE 5-4 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth CNS Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 SF-268 0.347 1.080 1.051 1.020 0.981 0.598 0.357 96 92 86 34 1 4.98E−6 >1.00E−4 >1.00E−4 SF-295 0.598 1.530 1.440 1.375 1.481 0.828 0.456 90 83 95 25 −24 4.35E−6 3.23E−5 >1.00E−4 SF-539 0.657 1.869 1.748 1.719 1.430 0.937 0.601 90 88 64 23 −9 2.18E−6 5.37E−5 >1.00E−4 SNB-19 0.279 0.934 0.892 0.887 0.867 0.650 0.307 94 93 90 57 4 1.34E−5 >1.00E−4 >1.00E−4 SNB-75 0.649 1.457 1.324 1.350 1.264 1.079 0.740 83 87 76 53 11 1.19E−5 >1.00E−4 >1.00E−4 U251 0.231 1.283 1.242 1.205 1.172 0.604 0.184 96 93 89 35 −21 5.38E−6 4.29E−5 >1.00E−4

TABLE 5-5 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Melanoma Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 LOX IMVI 0.311 2.100 1.927 1.830 1.766 0.867 0.244 90 85 81 31 −22 4.20E−6 3.89E−5 >1.00E−4 MALME-3M 0.403 0.725 0.715 0.696 0.687 0.498 0.145 97 91 88 30 −64 4.48E−6 2.07E−5 7.08E−5 M14 0.352 1.249 1.202 1.164 1.149 0.659 0.356 95 91 89 34 . 5.14E−6 >1.00E−4 >1.00E−4 SK-MEL-2 0.212 0.515 0.505 0.471 0.521 0.388 0.171 97 85 102 58 −20 1.27E−5 5.59E−5 >1.00E−4 SK-MEL-28 0.363 1.041 1.041 1.050 1.070 0.873 0.352 100 101 104 75 −3 2.10E−5 9.11E−5 >1.00E−4 SK-MEL-5 0.644 2.455 2.270 2.280 2.136 1.150 0.049 90 90 82 28 −92 3.93E−6 1.71E−5 4.44E−5 UACC-257 0.466 1.070 1.040 0.996 1.063 0.815 0.413 95 88 99 58 −11 1.30E−5 6.83E−5 >1.00E−4 UACC-62 0.828 2.206 2.103 1.986 2.030 1.655 0.662 92 84 87 60 −20 1.33E−5 5.61E−5 >1.00E−4

TABLE 5-6 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Ovarian Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 IGROV1 0.313 1.001 0.932 0.824 0.735 0.543 0.229 90 74 61 33 −27 2.55E−6 3.59E−5 >1.00E−4 OVCAR-3 0.237 0.743 0.766 0.717 0.626 0.260 0.137 104 95 77 4 −42 2.34E−6 1.25E−5 >1.00E−4 OVCAR-4 0.449 1.297 1.311 1.220 1.075 0.883 0.472 102 91 74 51 3 1.05E−5 >1.00E−4 >1.00E−4 OVCAR-5 0.372 1.072 1.054 0.999 1.056 0.912 0.506 97 90 98 77 19 5.93E−5 >1.00E−4 >1.00E−4 OVCAR-8 0.271 1.191 1.163 1.091 1.031 0.606 0.390 97 89 83 36 13 5.07E−6 >1.00E−4 >1.00E−4 SK-OV-3 0.521 1.313 1.243 1.228 1.150 0.874 0.586 91 89 79 44 8 6.95E−6 >1.00E−4 >1.00E−4

TABLE 5-7 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Renal Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 786-0 0.611 2.118 2.089 2.131 2.186 1.320 0.835 98 101 104 47 15 8.87E−6 >1.00E−4 >1.00E−4 A498 0.575 1.116 1.079 1.034 1.058 0.839 0.456 93 85 89 49 −21 9.31E−6 5.03E−5 >1.00E−4 ACHN 0.370 1.672 1.642 1.508 1.367 0.776 0.397 98 87 77 31 2 3.85E−6 >1.00E−4 >1.00E−4 CAKI-1 0.369 1.388 1.325 1.271 1.260 0.762 0.409 94 89 87 39 4 5.83E−6 >1.00E−4 >1.00E−4 RXF 393 0.826 2.065 2.024 1.973 1.829 1.355 0.919 97 93 81 43 7 6.43E−6 >1.00E−4 >1.00E−4 SN12C 0.518 1.551 1.421 1.257 1.326 1.108 0.508 87 71 78 57 −2 1.32E−5 9.27E−5 >1.00E−4 TK-10 0.190 0.513 0.518 0.464 0.457 0.306 0.196 102 85 83 36 2 5.00E−6 >1.00E−4 >1.00E−4 UO-31 0.483 1.268 1.113 1.058 1.059 0.678 0.475 80 73 73 25 −2 3.02E−6 8.59E−5 >1.00E−4

TABLE 5-8 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Prostate Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 PC-3 0.138 0.476 0.479 0.449 0.373 0.306 0.308 101 92 69 50 50 . >1.00E−4 >1.00E−4 DU-145 0.200 0.762 0.775 0.735 0.739 0.515 0.103 102 95 96 56 −49 1.14E−5 3.43E−5 >1.00E−4

TABLE 5-9 Log10 Concentration Panel/Cell Line Time Mean Optical Densities Percent Growth Breast Cancer Zero Ctrl −8.0 −7.0 −6.0 −5.0 −4.0 −8.0 −7.0 −6.0 −5.0 −4.0 GI50 TGI LC50 MCF7 0.451 2.118 1.797 1.793 1.201 0.894 0.318 81 80 45 27 −29 7.22E−7 2.98E−5 >1.00E−4 NCI/ADR-RES 0.476 1.685 1.621 1.586 1.530 0.934 0.567 95 92 87 38 8 5.68E−6 >1.00E−4 >1.00E−4 MDA-MB-231/ATCC 0.444 1.084 1.085 1.008 0.987 0.854 0.535 100 88 85 64 14 1.91E−5 >1.00E−4 >1.00E−4 HS 578T 0.415 0.913 0.854 0.861 0.819 0.710 0.405 88 90 81 59 −2 1.41E−5 9.14E−5 >1.00E−4 MDA-MB-435 0.426 1.511 1.527 1.479 1.525 1.043 0.021 101 97 101 57 −95 1.11E−5 2.37E−5 5.04E−5 BT-549 0.571 1.144 1.114 1.057 1.044 0.886 0.562 95 85 83 55 −2 1.22E−5 9.35E−5 >1.00E−4 T-47D 0.393 0.891 0.819 0.794 0.747 0.674 0.362 85 80 71 56 −8 1.26E−5 7.51E−5 >1.00E−4

While the invention has been described in terms of what is presently considered to be the most practical and preferred embodiments, it is to be understood that the invention needs not be limited to the disclosed embodiments. On the contrary, it is intended to cover various modifications and similar arrangements included within the spirit and scope of the appended claims which are to be accorded with the broadest interpretation so as to encompass all such modifications and similar structures.

CITATIONS

-   1. Bestilny, L. J.; Brown, C. B.; Miura, Y.; Robertson, L. D.;     Riabowol, K. T. Selective inhibition of telomerase activity during     terminal differentiation of immortal cell lines. Cancer Res. 1996,     56, 3796-802. -   2. Bodnar, A. G.; Ouellette, M.; Frolkis, M.; Holt, S. E.; Chiu, C.     P.; Morin, G. B.; Harley, C. B.; Shay, J. W.; Lichtsteiner, S.;     Wright, W. E. Extension of life-span by introduction of telomerase     into normal human cells. Science. 1998, 279, 349-52. -   3. Urquidi, V.; Tarin, D.; Goodison, S. Role of telomerase in cell     senescence and oncogenesis. Annu. Rev. Med. 2000, 51, 65-79. -   4. Smogorzewska, A.; de Lange, T. Regulation of telomerase by     telomeric proteins. Annu. Rev. Biochem. 2004, 73, 177-208. -   5. Peng, X.; Wu, Y.; Fan, J.; Tian, M.; Han, K. Colorimetric and     ratiometric fluorescence sensing of fluoride: tuning selectivity in     proton transfer. J. Org. Chem. 2005, 70, 10524-31. 

1. A compound of formula (I):

wherein R₁ is a substituent being one selected from a group consisting of: i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group; ii) a second substituent being one selected from a group consisting of (CH₂)_(n)X, a straight (CH₂)_(n) alkyl group, a (CH₂)_(n) alkoxyl group, a branched (CH₂)_(n) alkyl group, a C₃˜C₁₂ nephthenic group, and a C₃˜C₁₂ cyclic alkoxyl group, wherein 1≦n≦12, and X is a halogen; iii) a third substituent being one selected from a group consisting of a straight C₁˜C₈ alkyl group with a double-bond, a C₁˜C₈ alkoxyl group with a double-bond, a branched C₁˜C₈ alkyl group with a double-bond and a C₃˜C₈ nephthenic group with a double-bond; and iv) a fourth substituent of a C₅-C₁₂ heterocyclic group.
 2. A compound of claim 1, wherein R₁ is an ethyl group.
 3. A compound of claim 1, wherein one of the nephthenic group and the heterocyclic group further has at least one of an ortho-substitution, a meta-substitution and a para-substitution, and comprises at least a fifth substituent for any of the substitutions being one selected from a group consisting of an alkyl group with a C₁˜C₃ substituent branch, an amino group, a nitro group, a hydroxyl group and a cyan group, a C₁˜C₅ alkyl group, a halogen substituted C₁˜C₅ alkyl group, a C₁˜C₅ alkoxyl group, a halogen substituted C₁˜C₅ alkoxyl group, a C₁˜C₅ cyclic alkoxyl group, and a halogen substituted C₁˜C₅ cyclic alkoxyl group.
 4. A compound of claim 1, wherein the halogen is one selected from a group consisting of a fluorine, a chlorine, a bromine and an iodine.
 5. A compound of claim 1, wherein the second substituent is one selected from a group consisting of a methyl group, an ethyl group, a propyl group, a butyl group, an isobutyl group, a pentyl group, an isopentyl group, a cyclopentyl group, a heptyl group, an isoheptyl group, a cycloheptyl group, an octyl group, an isooctyl group, a cyclooctyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₅ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₅ alkyl group, alkoxyl derivatives of the mentioned alkyl groups, and halogenated derivatives of the mentioned alkyl groups.
 6. A compound of claim 1, wherein the third substituent is one selected from a group consisting of a vinyl group, a propenyl group, a butenyl group, an isobutenyl group, a pentenyl group, an isopentenyl group, a cyclopentenyl group, a hexenyl group, a cyclohexenyl group, a heptenyl group, an cycloheptenyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₃ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₃ alkyl group, alkoxyl derivatives of the mentioned groups, and halogenated derivatives of the mentioned groups.
 7. A compound of formula (III):

wherein either one of R₂ and R₃ is one of: i) a first substituent being one of a hydryl group and a sulfuryl-group; and ii) a second substituent being one selected from a group consisting of a C₁˜C₈ alkyl group, a C₁˜C₈ alkoxyl group, a C₃˜C₈ nephthenic group, and a C₃˜C₈ cyclic alkoxyl group, a straight alkyl group with a branch substitutent, a nephthenic group with a branch substitutent by a straight C₁˜C₅ alkyl group and halogenated derivatives of the mentioned substituent groups.
 8. A compound of claim 7, wherein the second substituent is one selected from a group consisting of a methyl group, an ethyl group, a propyl group, a butyl group, an isobutyl group, a pentyl group, an isopentyl group, a cyclopentyl group, a heptyl group, an isoheptyl group, a cycloheptyl group, an octyl group, an isooctyl group, a cyclooctyl group, a phenyl group, a benzyl group, a phenethyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₃ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₃ alkyl group, alkoxyl derivatives of the mentioned substituent groups, and halogenated derivatives of the mentioned substituent groups.
 9. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound having a following formula (I):

and at least one of an excipient and a carrier, wherein R₁ is a substituent being one selected from a group consisting of: v) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group; vi) a second substituent being one selected from a group consisting of (CH₂)_(n)X, a straight (CH₂)_(n) alkyl group, a (CH₂)_(n) alkoxyl group, a branched (CH₂)_(n) alkyl group, a C₃˜C₁₂ nephthenic group, and a C₃˜C₁₂ cyclic alkoxyl group, wherein 1≦n≦12, and X is a halogen; vii) a third substituent being one selected from a group consisting of a straight C₁˜C₈ alkyl group with a double-bond, a C₁˜C₈ alkoxyl group with a double-bond, a branched C₁˜C₈ alkyl group with a double-bond and a C₃˜C₈ nephthenic group with a double-bond; and viii) a fourth substituent of a C₅-C₁₂ heterocyclic group.
 10. A pharmaceutical composition of claim 9, wherein R₁ is an ethyl group.
 11. A pharmaceutical composition of claim 9, wherein one of the nephthenic group and the heterocyclic group further has at least one of an ortho-substitution, a meta-substitution and a para-substitution, and comprises at least a fifth substituent for any of the substitutions being one selected from a group consisting of an alkyl group with a C₁˜C₃ substituent branch, an amino group, a nitro group, a hydroxyl group and a cyan group, a C₁˜C₅ alkyl group, a halogen substituted C₁˜C₅ alkyl group, a C₁˜C₅ alkoxyl group, a halogen substituted C₁˜C₅ alkoxyl group, a C₁˜C₅ cyclic alkoxyl group, and a halogen substituted C₁˜C₅ cyclic alkoxyl group.
 12. A pharmaceutical composition as claimed in claim 9, wherein the halogen is one selected from a group consisting of a fluorine, a chlorine, a bromine and an iodine.
 13. A pharmaceutical composition as claimed in claim 9, wherein the second substituent is one selected from a group consisting of a methyl group, an ethyl group, a propyl group, a butyl group, an isobutyl group, a pentyl group, an isopentyl group, a cyclopentyl group, a heptyl group, an isoheptyl group, a cycloheptyl group, an octyl group, an isooctyl group, a cyclooctyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₅ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₅ alkyl group, alkoxyl derivatives of the mentioned alkyl groups, and halogenated derivatives of the mentioned alkyl groups.
 14. A pharmaceutical composition as claimed in claim 9, wherein the third substituent is one selected from a group consisting of a vinyl group, a propenyl group, a butenyl group, an isobutenyl group, a pentenyl group, an isopentenyl group, a cyclopentenyl group, a hexenyl group, a cyclohexenyl group, a heptenyl group, an cycloheptenyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₃ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₃ alkyl group, alkoxyl derivatives of the mentioned groups, and halogenated derivatives of the mentioned groups.
 15. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound having a following formula (III):

and at least one of an excipient and a carrier, wherein either one of R₂ and R₃ is one of: iii) a first substituent being one of a hydryl group and a sulfuryl-group; and iv) a second substituent being one selected from a group consisting of a C₁˜C₈ alkyl group, a C₁˜C₈ alkoxyl group, a C₃˜C₈ nephthenic group, and a C₃˜C₈ cyclic alkoxyl group, a straight alkyl group with a branch substituent, a nephthenic group with a branch substituent by a straight C₁˜C₅ alkyl group and halogenated derivatives of the mentioned substituent groups.
 16. A pharmaceutical composition of claim 15, wherein the second substituent is one selected from a group consisting of a methyl group, an ethyl group, a propyl group, a butyl group, an isobutyl group, a pentyl group, an isopentyl group, a cyclopentyl group, a heptyl group, an isoheptyl group, a cycloheptyl group, an octyl group, an isooctyl group, a cyclooctyl group, a phenyl group, a benzyl group, a phenethyl group, a straight alkyl group with a branch substituted by a straight C₁˜C₃ alkyl group, a nephthenic group with a branch substituted by a straight C₁˜C₃ alkyl group, alkoxyl derivatives of the mentioned substituent groups, and halogenated derivatives of the mentioned substituent groups. 